Bio-Rad Appoints New CFO, Sarah Young

TL;DR

Bio-Rad gets a new CFO, Sarah Young, starting May 6th. Morton moves to advisor role.

AI Summary

Bio-Rad Laboratories, Inc. announced on April 22, 2024, the appointment of Sarah E. Young as its new Chief Financial Officer, effective May 6, 2024. Young will succeed current CFO, Michael Morton, who will transition to a senior advisor role until his retirement on December 31, 2024. Young's compensation package includes an annual base salary of $450,000 and a target annual bonus of 60% of her base salary.

Why It Matters

The appointment of a new CFO can signal a shift in financial strategy or operational focus for the company, impacting investor confidence and future financial performance.

Risk Assessment

Risk Level: medium — Changes in key financial leadership can introduce uncertainty regarding future financial strategies and performance.

Key Numbers

• $450,000 — Annual Base Salary (Sarah Young's starting compensation)
• 60% — Target Annual Bonus (Sarah Young's potential bonus based on performance)

Key Players & Entities

• Bio-Rad Laboratories, Inc. (company) — Registrant
• Sarah E. Young (person) — Newly appointed Chief Financial Officer
• Michael Morton (person) — Outgoing Chief Financial Officer
• $450,000 (dollar_amount) — Sarah Young's annual base salary
• 60% (dollar_amount) — Sarah Young's target annual bonus percentage
• May 6, 2024 (date) — Effective date of Sarah Young's appointment
• December 31, 2024 (date) — Michael Morton's retirement date

FAQ

Key Financial Figures

• $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange

Filing Documents

• bio-20240422.htm (8-K) — 59KB
• ex101-bioxradlaboratoriesi.htm (EX-10.1) — 209KB
• bio-8k4262024xex991.htm (EX-99.1) — 7KB
• 0000012208-24-000031.txt ( ) — 482KB
• bio-20240422.xsd (EX-101.SCH) — 3KB
• bio-20240422_def.xml (EX-101.DEF) — 15KB
• bio-20240422_lab.xml (EX-101.LAB) — 27KB
• bio-20240422_pre.xml (EX-101.PRE) — 16KB
• bio-20240422_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting of Stockholders on April 23, 2024. The matters voted upon at the meeting and the results of those votes are set forth below. 1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows: Class of Common Stock Votes Votes Votes Broker to Elect For Against Abstaining Non-Votes Melinda Litherland Class A 17,178,561 2,491,017 8,267 1,944,423 Arnold A. Pinkston Class A 17,412,897 2,255,866 9,082 1,944,423 Jeffrey L. Edwards Class B 4,992,038 325 1 51,564 Gregory K. Hinckley Class B 4,991,949 325 90 51,564 Allison Schwartz Class B 4,990,900 1,374 90 51,564 Norman Schwartz Class B 4,990,900 1,374 90 51,564 2. The proposal to ratify the selection of KPMG LLP as the Company's independent auditors for the fiscal year ending December 31, 2024 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes Votes Votes Broker For Against Abstaining Non-Votes 7,151,808 51,181 3,166 - 3. The proposal to approve the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes Votes Votes Broker For Against Abstaining Non-Votes 6,870,787 84,984 4,378 246,006

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. A copy of the press release dated April 26, 2024 announcing the resignation of Dr. May and the appointment of Mr. Barry is furnished with this report as Exhibit 99.1.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 10.1 Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended 99.1 Press Release dated April 26, 2024 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: April 26, 2024 By: /s/ Courtney C. Enloe Courtney C. Enloe EVP, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR